January 2025 in “International Journal of Dermatology” Tofacitinib improved hair and nail conditions in a teen with alopecia areata.
22 citations
,
November 1979 in “Archives of dermatology” A woman with Fox-Fordyce disease had symptom relief using tretinoin cream.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
April 2018 in “Journal of Investigative Dermatology”
1 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
July 2025 in “Journal of Cosmetic Dermatology” Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.
2 citations
,
January 2023 in “Anais Brasileiros de Dermatologia”
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
May 2025 in “JEADV Clinical Practice” Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.
32 citations
,
April 2006 in “The Journal of Urology” Using finasteride with TIP extends time off period for prostate cancer patients.
June 2024 in “ESMO Gastrointestinal Oncology” The combination treatment showed a higher response rate but no significant survival benefits.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
March 2025 in “Indian Journal of Dermatology Venereology and Leprology” Tofacitinib is effective for treating alopecia totalis and universalis, with some patients experiencing significant hair regrowth.
July 2024 in “Journal of Controlled Release” Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
February 2024 in “Health Sciences” Botulinum neurotoxin A is effective and safe for treating various conditions, but more clinical trials are needed to fully assess its benefits and risks.
January 2008 in “Journal of Medicinal Chemistry” Finasteride may cause sexual and psychological side effects by affecting an enzyme related to epinephrine.
4 citations
,
January 2022 in “Dermatologic Therapy” Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
Tofacitinib helped a woman with total-body hair loss grow her hair back.
21 citations
,
August 1960 in “British journal of dermatology/British journal of dermatology, Supplement” Endoxan often causes hair loss, which usually starts in the third week of treatment.
8 citations
,
January 2013 in “Medicinal chemistry” The compound 4c showed strong potential as an anticancer agent.
March 2005 in “European Urology Supplements” October 2006 in “Dermatologic Surgery” Combining eflornithine cream with laser therapy effectively reduces unwanted facial hair in women.
24 citations
,
February 2023 in “BMC Complementary Medicine and Therapies” Forsythiaside A reduces kidney damage from sepsis by lowering inflammation and cell death.
January 2018 in “Haydarpaşa Numune Hastanesi tıp dergisi” Tamsulosin's sulfonamide group may contribute to floppy iris syndrome.
30 citations
,
December 2019 in “PLoS ONE” The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.
16 citations
,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
May 2020 in “riUfes (Universidade Federal do Espírito Santo)” Finasteride is stable except in high pH, and lactose and magnesium stearate should be replaced in formulations.
February 2006 in “Inpharma Weekly”